MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia

MYND’s Second CRA focuses on Novel Therapies for Neurological Diseases of the Brain VANCOUVER, BC, Jan. 12, 2022 /CNW/ – MYND Life Sciences Inc. (“MYND” or the “Company“) (CSE: MYND) (OTC: MYNDF) a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological diseases, today announced that it has entered into Collaborative...

Source

Article Link: MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia - Psilocybin Alpha